Lung Cancer
Volume 55, Issue 1 , Pages 101-107 , January 2007

Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multicenter phase II trial

  • A.G. Pallis

      Affiliations

    • Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
    • ,
  • Ch. Christofillakis

      Affiliations

    • Medical Oncology Unit, 401 Military Hospital of Athens, Greece
    • ,
  • E. Tselepatiotis

      Affiliations

    • Department of Internal Medicine, “Patision” General Hospital of Athens, Greece
    • ,
  • S. Agelaki

      Affiliations

    • Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
    • ,
  • L. Vamvakas

      Affiliations

    • Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
    • ,
  • J. Souglakos

      Affiliations

    • Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
    • ,
  • N. Vardakis

      Affiliations

    • Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
    • ,
  • A. Kalykaki

      Affiliations

    • Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
    • ,
  • A. Kotsakis

      Affiliations

    • Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
    • ,
  • A. Argiraki

      Affiliations

    • Department of Medical Oncology, “Iaso” General Hospital of Athens, Greece
    • ,
  • D. Mavroudis

      Affiliations

    • Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
    • ,
  • V. Georgoulias

      Affiliations

    • Department of Medical Oncology, University General Hospital of Heraklion, P.O. Box 1352, 71110 Heraklion, Crete, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30 2810 392750; fax: +30 2810 392802.

Received 12 July 2006 ,Revised 30 August 2006 ,Accepted 31 August 2006.

References 

  1. Ginsberg RJ, Vokes EE, Raben A. Non small cell lung cancer. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Principles and practice in oncology. 5th ed.. Philadelphia: Lippincott–Raven; 1997;p. 858–911
  2. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899–909
  3. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354–2362
  4. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–2103
  5. Sedlacek HH. Kinase inhibitors in cancer therapy: a look ahead. Drugs. 2000;59(3):435–476
  6. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997;3(4):515–522
  7. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001;7(7):1850–1855
  8. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21(12):2237–2246
  9. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149–2158
  10. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol. 2004;22(5):777–784
  11. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol. 2004;22(5):785–794
  12. Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res. 1986;46(8):3876–3885
  13. Norton L, Simon RG. Tumor size, sensitivity to therapy and design of treatment schedules. Cancer Treat Rep. 1977;61:1307–1317
  14. Hainsworth JD, Greco FA. The role of weekly docetaxel in the treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2002;3(Suppl. 2):S17–S22
  15. Hainsworth JD, Burris HA, Litchy S, Morrissey LH, Barton JH, Bradof JE, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A minnie pearl cancer research network phase II trial. Cancer. 2000;89(2):328–333
  16. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16(1):90–96
  17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214
  18. Cancer Therapy Evaluation Program. Common toxicity criteria. Version 2.0. DCTD, NCI, NIH, DHHS, 1998.
  19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10
  20. Simon R. How large should a phase II trial of a new drug be?. Cancer Treat Rep. 1987;71(11):1079–1085
  21. Collet D. Modelling survival data in medical research. 3rd ed.. Oxford: Blackwell Scientific; 1994;
  22. Altman GD. Practical statistics for medical research. London, UK: Chapman & Hall; 1991;
  23. Carney DN. Lung cancer—time to move on from chemotherapy. N Engl J Med. 2002;346(2):126–128
  24. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002;20(5):1335–1343
  25. Smith IE, O’Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001;19(5):1336–1343
  26. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005;23(33):8389–8395
  27. Souquet PJ, Tan EH, Rodrigues PJ, Van KR, Price A, Gatzemeier U, et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol. 2002;13(12):1853–1861
  28. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139
  29. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500

PII: S0169-5002(06)00467-3

doi: 10.1016/j.lungcan.2006.08.019

Lung Cancer
Volume 55, Issue 1 , Pages 101-107 , January 2007

Article Tools

* Image Usage & Resolution